Market Overview

RBCC, Therakine Initiate Phase II of Drug Delivery Development

Rainbow Coral Corp. (OTC: RBCC) and its joint venture partner,
Therakine, Ltd., are pleased to announce that they have reached a major
new milestone in the development of a revolutionary new drug delivery
technology. This week, the companies reached terms to initiate Phase II
of research and analysis on a new injectable, sustained-release
technology poised to vastly improve patients' use of a crucial drug in
the fight against drug and alcohol dependence.

Naltrexone is a prescription opioid receptor antagonist used primarily
in the management of alcohol and opioid dependence. Phase I of the joint
venture's research established excellent compatibility between the drug
and Therakine's hydrophobic injection matrix as well as a highly
promising release

See full press release

Posted-In: News Guidance FDA Management Global

 

Most Popular

Related Articles (RBCC)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free